Program Leader
Kenneth D. Tew, PhD DSc The Developmental Cancer Therapeutics (DCT) program’s scientific focus is the discovery of unique agents and pathways that will result in novel approaches to cancer therapy. DCT program members hold expertise in a wide spectrum of disciplines essential for the development of molecularly-targeted cancer therapeutics such as kinase inhibitors, drugs targeting redox pathways, lead compound selection by computational and medium throughput screening approaches, analysis of natural products and their derivatives, combinatorial chemistry, pharmacokinetics and pharmacodynamics. The DCT program has three primary themes: - Development of small molecule chemotherapeutic agents against novel cancer targets
- Modulation of cellular reactive oxygen species as a mechanism for regulating the growth and death of cancer cells
- Elucidation of complex cellular signaling pathways as potential novel targets for drug development
The DCT program consists of 36 members. The research portfolio for the DCT program is $7M, of which $3.7M is from the National Cancer Institute. The DCT program continues to develop mechanisms to foster collaboration including monthly meetings; program-specific seminars; symposia; a program-based, post-doctoral T32 training grant; a recent submission of a P20 Center of Biomedical Research Excellence; and the development of two new shared research resources – Drug Discovery/Screening and Drug Metabolism & Clinical Pharmacology. An exciting development for the DCT program is the opening of a new 113,000 gross ft2 Drug Discovery Building in 2010 in which HCC-supported shared resources and current and new scientists will be re-located. Contact Us
To find out more about this research program, e-mail the Program Leader:
Kenneth D. Tew, PhD, DSc
tewk@musc.edu
| 
